as 07-09-2025 11:31am EST
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
Founded: | 2018 | Country: | Germany |
Employees: | N/A | City: | BERLIN |
Market Cap: | 444.7M | IPO Year: | 2021 |
Target Price: | $11.00 | AVG Volume (30 days): | 5.6M |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.91 | EPS Growth: | N/A |
52 Week Low/High: | $1.03 - $2.98 | Next Earning Date: | 08-12-2025 |
Revenue: | $1,863,000 | Revenue Growth: | 572.56% |
Revenue Growth (this year): | 554.22% | Revenue Growth (next year): | -81.02% |
ATAI Breaking Stock News: Dive into ATAI Ticker-Specific Updates for Smart Investing
Zacks
14 days ago
Insider Monkey
15 days ago
TipRanks
20 days ago
TipRanks
20 days ago
WSJ
20 days ago
GlobeNewswire
a month ago
GlobeNewswire
a month ago
TipRanks
2 months ago
The information presented on this page, "ATAI ATAI Life Sciences N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.